ASH 2022: Dr. Nirav Shah on Pirtobrutinib for Richter’s Transformation
Our own Dr. Brian Koffman interviewed Dr. Nirav Shah, Associate Professor of Medicine at Medical College of Wisconsin, focusing on hematological malignancies. They discussed the latest results from a clinical trial of pirtobrutinib, a new reversible Bruton tyrosine kinase (BTK) inhibitor, for treating Richter transformation.